Company intelligence / Profile preview

Biosensis

Thebarton, South Australia, Australiabiosensis.com ↗

Ownership: Private
Employees: ~30
Development stage: Commercial

Overview

Biosensis is a leading provider of neuroscience-focused research reagents including ELISA kits, antibodies, proteins, and staining reagents. The company is recognized for its expertise in neurotrophins and neurodegenerative disease biomarkers. It recently expanded into superparamagnetic iron oxide nanoparticle technology for biomedical applications through an exclusive agreement with Imagion Biosystems[1][3][4].

Therapeutic areas: Metabolic DisordersRare DiseasesNeurology
Modalities: AntibodyMonoclonal antibodyProteinPeptidesSmall molecule (inhibitors)Nanoparticle
Industry: Protein Biomarker Diagnostics

Partnerships

Imagion Biosystems (PrecisionMRX® SPION technology licensing)Sapphire Bioscience (distribution partner in Australia/New Zealand for nanoparticles)

Beyond the preview

Go deeper on Biosensis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Biosensis.

Explore the full profile